Branch atheromatous disease and treatment

Honglian Duan; Ho Jun Yun; Xiaokun Geng; Yuchuan Ding

doi:10.4103/bc.bc_56_22

Branch atheromatous disease and treatment

Brain Circ. 2022 Dec 6;8(4):169-171. doi: 10.4103/bc.bc_56_22. eCollection 2022 Oct-Dec.

Authors

Honglian Duan¹, Ho Jun Yun², Xiaokun Geng^{1

2

3}, Yuchuan Ding²

Affiliations

¹ Department of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
² Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI 48201, USA.
³ Department of Neurology, Luhe Institute of Neuroscience, Capital Medical University, Beijing, China.

Abstract

Branch atheromatous disease (BAD) is a subtype of ischemic stroke caused by perforating arteries occlusion due to proximal atherosclerosis of the arteries. Early neurological deterioration and recurrent stereotyped transient ischemic attacks are typical clinical manifestations of BAD. The optimal treatment for BAD has not been determined. This article explores a possible mechanism of BAD and effective treatment measures to prevent early progression and attack of transient ischemic events. This article explains the current status of intravenous thrombolysis, tirofiban, and argatroban for BAD and subsequent prognosis.

Keywords: Argatroban; branch atheromatous disease; early neurological deterioration; intravenous thrombolytic therapy; tirofiban.